Cargando…

The role of mitochondria in the resistance of melanoma to PD-1 inhibitors

Malignant melanoma is one of the most common tumours and has the highest mortality rate of all types of skin cancers worldwide. Traditional and novel therapeutic approaches, including surgery, targeted therapy and immunotherapy, have shown good efficacy in the treatment of melanoma. At present, the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Fei, Yang, Lu-han, Liu, Jiao, Wang, Jian, Fan, Lianpeng, Duangmano, Suwit, Liu, Hao, Liu, Minghua, Wang, Jun, Zhong, Xiaolin, Zhang, Zhuo, Wang, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207731/ https://www.ncbi.nlm.nih.gov/pubmed/37221594 http://dx.doi.org/10.1186/s12967-023-04200-9

Ejemplares similares

Advancements in understanding the role of microRnas in regulating macrophage polarization during acute lung injury
por: Zhang, Jianhua, et al.
Publicado: (2023)

Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway
por: Zhang, Zhuo, et al.
Publicado: (2023)

Development of E-ice-COLD-PCR assay combined with HRM analysis for Nucleophosmin1 gene mutation detection in acute myelogenous leukemia
por: Kongta, Rattana, et al.
Publicado: (2022)

Effect of malarial infection on haematological parameters in population near Thailand-Myanmar border
por: Kotepui, Manas, et al.
Publicado: (2014)

Cucurbitacin B Causes Increased Radiation Sensitivity of Human Breast Cancer Cells via G2/M Cell Cycle Arrest
por: Duangmano, Suwit, et al.
Publicado: (2012)

Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation
por: Duangmano, Suwit, et al.
Publicado: (2012)

Corrigendum to “Cucurbitacin B Causes Increased Radiation Sensitivity of Human Breast Cancer Cells via G2/M Cell Cycle Arrest”
por: Duangmano, Suwit, et al.
Publicado: (2015)

Antiproliferative Effects of Cucurbitacin B in Breast Cancer Cells: Down-Regulation of the c-Myc/hTERT/Telomerase Pathway and Obstruction of the Cell Cycle
por: Duangmano, Suwit, et al.
Publicado: (2010)

Effects of Malaria Parasite Density on Blood Cell Parameters
por: Kotepui, Manas, et al.
Publicado: (2015)

Introduction of new alternative pipeline using multiplexed fast COLD‑PCR together with sequencing approach highlighting pharmacoeconomics by detection of CYP variants
por: Nandar, Yu Myat, et al.
Publicado: (2022)

Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
por: Xie, Xiao-Qing, et al.
Publicado: (2023)

Efficacy of melanoma patients treated with PD-1 inhibitors: Protocol for an overview, and a network meta-analysis of randomized controlled trials
por: Li, Jing, et al.
Publicado: (2019)

Targeting Mitochondria in Melanoma
por: Aminzadeh-Gohari, Sepideh, et al.
Publicado: (2020)

Healthy mitochondria inhibit the metastatic melanoma in lungs
por: Fu, Ailing, et al.
Publicado: (2019)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
por: Liu, Ye, et al.
Publicado: (2021)

ZWZ-3, a Fluorescent Probe Targeting Mitochondria for Melanoma Imaging and Therapy
por: Liu, Zengjin, et al.
Publicado: (2022)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
por: Wang, Xuanyi, et al.
Publicado: (2020)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
por: Yang, Fang, et al.
Publicado: (2021)

A Novel Drug Modulator Diarylheptanoid (trans-1,7-Diphenyl-5-hydroxy-1-heptene) from Curcuma comosa Rhizomes for P-glycoprotein Function and Apoptosis Induction in K652/ADR Leukemic Cells
por: Viriyaadhammaa, Natsima, et al.
Publicado: (2022)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
por: Wang, Fengling, et al.
Publicado: (2023)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
por: Faure, Marjorie, et al.
Publicado: (2018)

RNF8 enhances the sensitivity of PD-L1 inhibitor against melanoma through ubiquitination of galectin-3 in stroma
por: Guo, Yanan, et al.
Publicado: (2023)

Effects of postoperative radiotherapy and docetaxel and PD-1 inhibitors on the survival and safety of glioblastoma patients: a systematic review and meta-analysis
por: Fan, Yingjun, et al.
Publicado: (2022)

Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population
por: Wang, Chen, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials
por: Li, Fei, et al.
Publicado: (2021)

Cytotoxic and Antiproliferative Effects of Diarylheptanoids Isolated from Curcuma comosa Rhizomes on Leukaemic Cells
por: Viriyaadhammaa, Natsima, et al.
Publicado: (2020)

PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis
por: He, Runzhi, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
por: Escandon, Julia, et al.
Publicado: (2017)

Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma
por: Trilla-Fuertes, Lucía, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma treated with PD‐1 inhibitor: Two case reports
por: Jiang, Tao, et al.
Publicado: (2023)

Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work
por: Li, Xia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4uemjslr1cnhqnd8jo4brtagje